Qiagen N.V. (NYSE:QGEN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have earned a consensus rating of “Hold” from the fourteen research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $42.4250.

Several brokerages have issued reports on QGEN. Barclays set a $38.00 price target on shares of Qiagen and gave the company an “equal weight” rating in a research report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price objective on shares of Qiagen in a report on Thursday, April 30th. Weiss Ratings lowered Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 29th. Stifel Nicolaus set a $36.00 target price on Qiagen and gave the stock a “hold” rating in a report on Monday, May 18th. Finally, Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th.

Institutional Trading of Qiagen

Several institutional investors have recently added to or reduced their stakes in the stock. Boston Partners bought a new position in shares of Qiagen in the 3rd quarter worth about $179,450,000. Norges Bank bought a new stake in shares of Qiagen during the 4th quarter valued at about $166,500,000. Dimensional Fund Advisors LP bought a new stake in shares of Qiagen during the 3rd quarter valued at about $58,079,000. Price T Rowe Associates Inc. MD grew its stake in Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares during the period. Finally, Deutsche Bank AG grew its stake in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Qiagen News Roundup

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen reported second-quarter adjusted EPS of $0.62, above the $0.60 consensus estimate, while revenue of $535 million exceeded expectations of $527.5 million. Revenue was broadly unchanged year over year, but the company said its growth pillars delivered 5% growth at constant exchange rates and that sales exceeded its prior outlook for a decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 EPS outlook of approximately $2.43, in line with analyst expectations, while maintaining high profitability. Qiagen Earnings Conference Call
• Neutral Sentiment: Management’s second-quarter earnings call and presentation provided additional detail on the performance of Qiagen’s growth pillars and the company’s outlook, but did not materially change the full-year EPS forecast. Qiagen N.V. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter guidance was below consensus: EPS of $0.62 versus $0.63 expected and revenue of $538.3 million to $543.7 million versus $552.7 million expected. The revenue shortfall indicates analysts may need to reduce near-term estimates.
• Negative Sentiment: Although full-year EPS guidance matched consensus, full-year revenue guidance of roughly $2.1 billion was below the approximately $2.2 billion analyst estimate, tempering the impact of the quarterly beat.

Qiagen Stock Performance

NYSE:QGEN opened at $41.71 on Friday. The stock’s 50-day moving average is $39.32 and its 200-day moving average is $41.69. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The stock has a market cap of $8.59 billion, a P/E ratio of 21.37, a price-to-earnings-growth ratio of 4.19 and a beta of 0.63.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The business had revenue of $535.00 million during the quarter, compared to analyst estimates of $527.50 million. During the same quarter last year, the business earned $0.60 EPS. The firm’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were paid a $0.35 dividend. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s payout ratio is presently 18.32%.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.